Core B

核心B

• 批准号: 10339364
• 负责人: Galit Alter
• 金额: $ 99.39万
• 依托单位: BETH ISRAEL DEACONESS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-02-01 至 2025-01-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10339364
• 关键词: Antibodies; Antibody Response; Binding; Biological Assay; Biometry; Cell physiology; Cells; Clinical; Complement; Data; Development; Ensure; Epitopes; Fc Receptor; Goals; HIV vaccine; Human; Human Resources; Humoral Immunities; Immune; Immune response; Immunity; Immunologic Monitoring; Immunologics; Immunology; Infection; Infection prevention; Infrastructure; Institutes; Israel; Leadership; Lectin; Link; Macaca mulatta; Measurement; Mediating; Medical center; Mission; Neutralizing antibody assay; Positioning Attribute; Process; Proteins; Reagent; Regimen; Research Personnel; Role; SIV; Sampling Studies; Serology; Serum; Services; Standardization; Statistical Data Interpretation; System; Technical Expertise; Vaccination; Vaccines; Virus Diseases; Work; neutralizing antibody; nonhuman primate; pathogen; prevent; programs; recruit; response; simian human immunodeficiency virus; vaccine-induced immunity

Core B (Immunology Core) will provide standardized humoral immune monitoring assay services for evaluating antibody responses elicited by Ad26-Env/Gag/Pol prime, Env gp140 protein boost (Ad26/Env) vaccine regimens in the studies described in this IPCAVD program. Core B leadership will work closely with investigators responsible for the studies described in Project 1 and Project 2 and will participate actively in the scientific mission of the overall IPCAVD program. The primary goal of Core B is to provide the leadership and the technical expertise to ensure that all vaccine-induced humoral responses will be profiled in a standardized fashion and that the IPCAVD leadership is kept abreast of the latest developments in assessing vaccine-induced neutralizing and non-neutralizing humoral immunity, particularly in relation to their ability to prevent viral infection. To accomplish these goals, we propose the following three Specific Aims: Specific Aim 1. To perform standardized neutralizing antibody (NAb) assays in both NHP and humans Specific Aim 2. To perform standardized non-neutralizing antibody assays in both NHP and humans Specific Aim 3. To integrate all antibody data into a Systems Serology profiling approach to define correlates of protective immunity

核心B（免疫学核心）将为 评估AD26-ENV/GAG/POL PRIME引起的抗体反应，ENV GP140蛋白增强（AD26/END） 在此IPCAVD计划中描述的研究中，疫苗方案。核心B领导将紧密工作 负责项目1和项目2中描述的研究的研究人员将积极参与 总体IPCAVD计划的科学任务。核心B的主要目标是提供领导 以及确保所有疫苗引起的体液反应的技术专长都将在 标准化的时尚，IPCAVD领导与评估的最新发展保持一致 疫苗引起的中和和非中和体液免疫，特别是与其能力有关 预防病毒感染。为了实现这些目标，我们提出以下三个具体目标： 特定目的1。在NHP和人类中执行标准化的中和抗体（NAB）测定 特定目的2。在NHP和人类中执行标准化的非中和抗体测定 特定目的3。将所有抗体数据集成到系统血清学分析方法中以定义相关性 保护性免疫